Triple therapy for COPD : Understanding evidence is complicated
Bibliographic record
Abstract
Background: Recent Canadian and international guidelines for management of chronic obstructive pulmonary disease (COPD) recommend single inhaler triple therapy (long-acting muscarinic antagonist/longacting beta agonist/inhaled corticosteroid) as first-line treatment or as escalation from dual therapy for “high risk” patients who experienced at least 1 severe or 2 moderate exacerbations during the previous year. While they differ as to other eligibility criteria for triple therapy, these new recommendations could increase inappropriate prescriptions. In British Columbia, singleinhaler triple therapy is increasing rapidly. Aims: This Therapeutics Letter critically appraises available evidence about triple therapy for “high risk” COPD patients. Findings: No randomized controlled trial (RCT) has evaluated first-line triple therapy in people newly diagnosed with COPD. Three RCTs enrolled “high risk” patients (N=20,396) at a mean of 8 years after COPD diagnosis. Most were already using ICS and many had a history of asthma. Results cannot be extrapolated to treatment-naïve patients treated initially with triple therapy. We found unconvincing the RCT evidence that triple therapy reduces exacerbations. Like the US FDA’s Advisory Committee, we could not confirm that triple therapy reduces mortality. Furthermore, retrospective real-world data indicate that triple therapy achieves no significant reduction in exacerbations, but increases pneumonia and total mortality. Conclusions: Current evidence does not support first-line triple therapy in treatment-naïve COPD patients, nor routinely adding ICS for people already using a LAMA/LABA inhaler. Clinicians should prioritize smoking cessation, immunization, and inhaler technique over pharmacological intensification, and ensure evidence-informed shared decision-making.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.108 | 0.281 |
| Meta-epidemiology (narrow) | 0.002 | 0.002 |
| Meta-epidemiology (broad) | 0.008 | 0.005 |
| Bibliometrics | 0.010 | 0.007 |
| Science and technology studies | 0.002 | 0.011 |
| Scholarly communication | 0.014 | 0.029 |
| Open science | 0.007 | 0.008 |
| Research integrity | 0.012 | 0.024 |
| Insufficient payload (model declined to judge) | 0.005 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".